In Big Win for JDRF’s Coverage2Control Campaign, Anthem Decides to Cover Artificial Pancreas Systems
JDRF, the leading global organization funding type 1 diabetes (T1D) research, today announced that its Coverage2Control campaign swayed
AP systems monitor blood glucose levels and automatically provide the right amount of insulin -- a revolutionary advancement that dramatically reduces T1D-related complications and risks. But they are largely out of reach when not covered by insurance, due to their out-of-pocket costs.
"This is a great victory for the T1D community. By taking this tremendous step,
JDRF launched the Coverage2Control campaign in May to urge insurance companies to provide coverage that works for people with diabetes. Within months, the campaign created a swell of momentum. Twelve health organizations --including leading endocrinologist and diabetes educator groups -- joined as campaign partners, more than 50,000 people signed a petition that JDRF then delivered to the nation's 25 largest insurance companies, and thousands more people have been using a grassroots platform to send personalized letters to their insurers. JDRF also reached out to executives at the 25 largest health insurance companies to have direct conversations about their coverage policies.
This announcement demonstrates the power of the T1D community's collective voice: A major health insurer has adopted a policy that offers a new path for managing diabetes.
Along with
The first AP system came to market in 2017 after years of research and clinical trials. Over the past decade, JDRF has championed the development of AP technology through direct funding and collaboration with academic, research, government and industry partners -- including advocating for the government's primary research program, the Special Diabetes Program -- which expired on
JDRF will continue to work with insurance companies, urging them to regularly review and improve their coverage policies as new technology and therapies become available, and additional AP systems come to market.
Already, many next-generation AP systems are in development. As technology advances, these systems will become better and better at predicting blood glucose changes and providing tightly controlled insulin dosing that virtually eliminates life-threatening hypoglycemic and hyperglycemic episodes. It's crucial that insurance companies cover these systems -- and not limit coverage to one brand -- when they are
People in the T1D community can continue to send letters directly to their insurer in less than 60 seconds using JDRF's online platform. To stay updated and find other ways to engage in the campaign, visit Coverage2Control.com.
ABOUT T1D
Type 1 diabetes (T1D) is an autoimmune disease in which a person's pancreas stops producing insulin, a hormone that enables people to get energy from food. It occurs when the body's immune system attacks and destroys the insulin-producing cells in the pancreas, called beta cells. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. Its onset has nothing to do with diet or lifestyle. There is nothing you can do to prevent T1D, and -- at present -- nothing you can do to get rid of it.
ABOUT JDRF
JDRF is the leading global organization funding type 1 diabetes (T1D) research. Our mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than
This document was posted showing the date:
U of G Social Sciences, Humanities Research Gets $3.4 Million in Federal Support
American Family Insurance Expands Board of Directors With Election of Bill Westrate, Fabian Fondriest
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News